The State Administration of Drug Administration has approved the listing of two innovative drugs.

Recently, the National Medical Products Administration approved the listing of the first-class innovative drug Opresone tablets, declared by Takeda Pharmaceuticals U.S.A., Inc., through the priority review and approval process. The drug is used for patients with type 1 narcolepsy aged 16 and above. Additionally, the National Medical Products Administration recently approved the listing of the first-class innovative drug Sodium oxybate sustained-release tablets, declared by Sichuan Hisun Pharmaceutical Co., Ltd., through the priority review and approval process. This drug is suitable for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not received complement inhibitor therapy before.